BioElectronics Receives New OTC Product Approvals

Main Category: Pain / Anesthetics
Also Included In: Women's Health / Gynecology;  Regulatory Affairs / Drug Approvals;  Medical Devices / Diagnostics
Article Date: 30 Jun 2010 - 1:00 PDT

email to a friend   printer friendly   opinions  

BioElectronics Corporation (PINKSHEETS: BIEL), developers of innovative pain-relieving medical devices, announced that its Allay™ Menstrual Pain Therapy product has been approved for over the counter sale by Health Canada for the treatment of menstrual pain symptoms, including cramps and abdominal pain, and for reducing the use of pain medication associated with menstruation, while ActiPatch™ is now approved by the South Korea Food and Drug Administration (KFDA) for reduction of muscle pain.

The new approvals of our technology in these two markets build upon the growing momentum of global expansion for BioElectronics' unique pain-relieving technology. Additionally, the Company recently secured an agreement for distribution of its products in Russia.

The Allay and ActiPatch products provide a safe, drug-free treatment for pain suffered by millions of people through the use of innovative pulse electromagnetic energy technology to reduce inflammation, edema and pain.

"With its proven technology and established clinical platform, Allay and ActiPatch are very unique brands in both Canada and Korea," said Arnon Horev, Vice President of Sales and Marketing with BioElectronics. "These latest approvals open the door to new markets for our products and will allow us to further expand access to these effective, safe topical and drug-free options for pain relief."

Source:
BioElectronics Corporation

• Additional
• References
• Citations